Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (August 15th Preview)
-
FDA accelerated approval for Zenbexus expands CELMoDs in multiple myeloma
The FDA has granted accelerated approval to Bristol Myers Squibb’s Zenbexus (iberdomide) for adult patients with advanced multiple myeloma that has returned or is refractory to treatment, clearing a first-of-its-kind (for BMS) successor therapy in the CELMoDs class. Zenbexus is indicated in combination with daratumumab and hyaluronidase-fihj, plus dexamethasone, in the second-line setting after at least one prior therapy. The approval follows Phase 3 evidence supporting improved depth of response, with the regimen raising the proportion of patients achieving minimal residual disease (MRD) negativity compared with a bortezomib (Velcade)-based control. The company expects additional results that could support conversion to full approval as well as continued development in other disease phases. Zenbexus also reinforces BMS’s push to sustain its myeloma franchise as generic competition pressures older backbones. The accelerated clearance could drive prescriber adoption if ongoing studies confirm whether MRD improvements translate into longer progression-free or overall survival.
-
Zenbexus approval as first-in-class CELMoDs franchise cornerstone
Bristol Myers Squibb’s Zenbexus (iberdomide) also marked the first global FDA nod for a CELMoDs protein-degradation approach in multiple myeloma, according to separate coverage highlighting the drug class positioning and MRD-based regulatory path. The accelerated approval leverages a deeper remission endpoint rather than traditional response rates. Analysts framed the approval as a potential inflection point for competitive sequencing in second-line myeloma, where Zenbexus is designed to be used alongside daratumumab and dexamethasone. The reporting also points to an internal development roadmap for additional studies, including maintenance and earlier-line strategies. With a reported launch price and expectations for uptake, the decision sets up a near-term competitive test for combination regimens against established daratumumab-based standards.
-
Cell therapy funding and update: Capricor seeks FDA review after DMD setbacks
Capricor Therapeutics moved to preserve its Duchenne muscular dystrophy (DMD) regulatory path after an adverse FDA advisory committee outcome, saying it will seek FDA review of additional data and analyses. The company framed the next step as an attempt to narrow its approval approach and strengthen the evidence package. Market reaction followed with a reported stock surge tied to the prospect of an FDA willingness-to-review update, according to coverage of the company’s strategy and CEO comments. The update keeps Capricor’s allogeneic cell therapy deramiocel in focus as an example of how DMD programs are navigating an approval bar shaped by committee feedback and evidence refinements.
-
AI+biotech finance: Precision immunology startup Boulevard emerges from stealth with $65M
Boulevard Bio emerged from stealth with approximately $65 million in launch financing, backed entirely by Deerfield Management and its internal discovery engine, 3DC. The company is developing a quarterly-dosing concept for B cell-driven autoimmune disease using multi-specific antibodies, with Boulevard’s initial focus on IgA nephropathy. At the center of the platform is BLVD101, a bispecific targeting BAFF and APRIL—key cytokines involved in B cell survival and activation. Interim Phase 1 healthy-volunteer data were cited to support a potential 12-week dosing interval, aiming to reduce treatment burden relative to more frequent regimens. Boulevard’s structure—spinning out after advancing assets through early clinical development within Deerfield—signals a growing internal-to-external therapeutics model for reducing early risk while maintaining platform focus.
-
Protein sequencing systems: Quantum-Si pushes Proteus launch to 2Q 2027 and cuts 20% staff
Quantum-Si disclosed it is laying off about 20% of its workforce and delaying the Proteus protein sequencing system launch to the second quarter of 2027. The proteomics company said the change is tied to adding an “integrated instrument design cycle” before moving to production, citing repeatability and consistency risks across internally produced integrated units. Alongside the personnel reductions, Quantum-Si estimated cost actions generating roughly $12 million in annualized operating expenses, extending its cash runway from Q2 2028 to Q4 2028. The company also updated Proteus reagent plans for amino-acid coverage at launch. The Proteus timing shift highlights the gap between prototype performance and scalable manufacturing readiness for next-generation proteomics platforms.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.